RGLS — Regulus Therapeutics Share News
0.000.00%
Last trade - 00:00- $563.57m
- $498.20m
Brief: Novartis Announces Expiration Of Hart-Scott-Rodino Waiting Period Of Regulus Therapeutics Tender Offer
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics
Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Avepoint, Meta, United Therapeutics
U.S. STOCKS ON THE MOVE-Oddity Tech, International Paper, Vulcan
U.S. STOCKS ON THE MOVE-Generac, Regulus Therapeutics, Garmin
Regulus Therapeutics' stock price doubles on Novartis's buyout offer
U.S. STOCKS ON THE MOVE-Etsy, GE HealthCare, Caterpillar
Brief: Regulus Therapeutics Upon Termination Of Merger Deal Under Some Circumstances, Co To Pay Parent Termination Fee Of $27.3 Million
Regulus Therapeutics' stock price doubles on Novartis's buyout offer
Novartis to buy Regulus Therapeutics for up to $1.7 billion (updated)
Brief: Regulus Therapeutics Enters Into Agreement To Be Acquired By Novartis AG
Novartis to buy Regulus Therapeutics for up to $1.7 billion
Brief: Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney Disease
Brief: Regulus Therapeutics Q4 Operating Expenses USD 13.746 Million
Regulus Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Regulus Therapeutics Announces Completion Of Enrollment In Fourth Cohort Of Phase 1B Multiple-Ascending Dose Clinical Trial